Chapter 8 — Further Reading

Tier 1 — Verified canonical

The primary sources you can read yourself.

DailyMed carries the complete approved labeling for Ozempic, Wegovy, and Rybelsus. Each contains: the approved indications (note how narrow they are), the boxed warning, the full adverse reactions tables with rates, the Clinical Pharmacology section, and summaries of the pivotal trials.

Read the adverse reactions table. It gives the actual rates of the gastrointestinal effects in the trials, side by side with placebo. It is a better source than any secondary account, and the placebo column is frequently a surprise.

Drugs@FDA holds the approval records, including the review documents. These are dense and extraordinarily informative — they contain the regulators' own analysis of the evidence, including concerns raised and how they were resolved.

ClinicalTrials.gov — search "STEP semaglutide," "SUSTAIN semaglutide," "SELECT semaglutide," or "PIONEER semaglutide." Each trial's registry entry gives the eligibility criteria, the pre-specified primary endpoint, the enrollment, and the completion date. Read the eligibility criteria before you read any result; it makes the population-swap error very hard to fall into.

PubMed indexes the published trial reports. The major STEP, SUSTAIN, SELECT, and PIONEER publications are in prominent journals and their abstracts are free.

Professional society guidance on periprocedural management. Anesthesiology societies have issued guidance regarding GLP-1 receptor agonists and aspiration risk. This is a good example of post-marketing knowledge becoming clinical practice, and the documents are public.

Tier 2 — Attributed, specifics unverified

On the STEP results. Semaglutide 2.4 mg weekly in adults with overweight or obesity without diabetes produced mean weight change of about −15% from baseline at 68 weeks versus roughly −2.4% on placebo, with both arms receiving lifestyle intervention. In adults with type 2 diabetes, the corresponding figure was roughly −10%.

On SELECT. Roughly 17,000 adults with established cardiovascular disease and overweight or obesity without diabetes, followed about three years: a 20% relative reduction in major adverse cardiovascular events (hazard ratio about 0.80); in absolute terms roughly 8% to 6.5%, about 1.5 percentage points. Manufacturer-sponsored.

On SUSTAIN 6. Semaglutide in type 2 diabetes at high cardiovascular risk over about two years produced a statistically significant reduction in major adverse cardiovascular events. This book states the direction and does not quote a hazard ratio.

On gastrointestinal adverse effect rates. Commonly reported in the range of roughly a third to a half depending on the specific effect, the dose, and the trial, and usually mild to moderate with attenuation over weeks. The label's table is the authoritative source and should be preferred to any range quoted here.

On the pancreatitis signal. Extensively examined in trials and observational studies; a substantial increased risk has not been established, though the concern remains labeled and monitored.

On the rodent thyroid finding. GLP-1 receptor agonists produced thyroid C-cell tumors in rodents; rodent thyroid C-cells express GLP-1 receptors far more abundantly than human ones. No human increase has been demonstrated, and medullary thyroid carcinoma is rare enough that detecting a modest relative increase is genuinely difficult.

On lean mass. Body composition studies indicate that a meaningful proportion of weight lost on GLP-1 receptor agonists is lean mass, in a range broadly comparable to other weight-loss interventions. Whether this translates into functional decline is not well established; trials measuring physical function have generally reported improvement.

On discontinuation. Extension and withdrawal studies have reported substantial weight regain following discontinuation, with cardiometabolic parameters moving back toward baseline. Precise proportions vary by study and duration.

On the historical weight-loss drug withdrawals. Fenfluramine-phentermine and valvular heart disease; sibutramine and increased cardiovascular events in a required outcomes trial; rimonabant and psychiatric adverse effects. All are well documented; specific withdrawal dates and jurisdictions vary and are not stated here.

Tier 3 — Illustrative and constructed

• The three-modification ASCII map, the override-versus-replace comparison, and the candidate-mechanism list in Case Study 1 are this book's own teaching devices.
• The worked twelve-field dossier entry for semaglutide is a demonstration constructed for this book from publicly available information; Field 11 (Verdict) is deliberately left blank for the reader.
• Figures 8.3 and 8.5 render real published trials in this book's six-field format; the format is the book's own.
• The failure-pattern table in Case Study 2 is this book's synthesis of a documented historical pattern.
• The "honest sentence" in Case Study 1's Hype Check is written for this book.

If you only do one thing

Open the Wegovy label on DailyMed and read two sections.

Section 1, Indications and Usage. Note how narrowly it is written — a BMI threshold, or a lower threshold with a specific comorbidity, plus "as an adjunct to a reduced-calorie diet and increased physical activity." That last clause is the trial protocol, written into the label.

Section 6, Adverse Reactions. Read the table. Note the placebo column. Note how many effects occur in both arms and how the difference is smaller than the drug-arm number alone suggests.

Then compare both to any consumer-facing description of the drug you can find. The gap is not dishonesty; it is compression, and Chapter 6 explained the mechanism. But the label is free and it takes ten minutes.

Looking ahead

Chapter 9 covers tirzepatide and the multi-agonists. The single most useful preparation: look up SURMOUNT-1 on ClinicalTrials.gov and find its primary endpoint and its analysis populations.

You are about to meet a trial that honestly reports two different weight-loss figures for the same dose over the same duration. Chapter 5 §5.9 explained why. Chapter 9 works it in full, and it is the single most useful statistical skill in Part II.